Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | STK16 | O75716 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490718 | 0.84 | ALK (0.50) | SLC22A12NCF1ALKGAKHTT | |
| SCHEMBL1332713 | 0.79 | PARP1 (0.47) | LMNAMAPTRIPK2HTTALOX15 | |
| SCHEMBL14690611 | 0.79 | SLC22A12 (0.51) | SLC22A12NCF1ALKCHEK1PIM1 | |
| SCHEMBL30819181 | 0.79 | PARP1 (0.47) | LMNAMAPTRIPK2HTTALOX15 | |
| SCHEMBL29896761 | 0.79 | SLC22A12 (0.51) | SLC22A12NCF1ALKCHEK1PIM1 | |
| SCHEMBL28140818 | 0.78 | SMN1; SMN2 (0.44) | SLC22A12NCF1ALKCHEK1PIM1 | |
| SCHEMBL3268768 | 0.76 | NR4A2 (0.61) | CCNCCDK8MAPTGAKRIPK2 | |
| SCHEMBL729828 | 0.76 | SLC22A12 (0.49) | SLC22A12NCF1ALKCHEK1PIM1 | |
| SCHEMBL5539379 | 0.76 | HTR1A (0.54) | SLC22A12FLT3PIM3CDK8LMNA | |
| SCHEMBL591523 | 0.76 | CDK8 (0.49) | SLC22A12CCNCCDK8MAPTGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120035581-A | Amplifying preparation method of 6-bromo-4-hydroxyquinoline | 上海再启生物技术有限公司 | 2025-05-23 | — | — | CN | claimed |
| US-20210246128-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-08-12 | — | — | US | claimed |
| EP-3807248-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | Council of Scientific and Industrial Research (IN) | 2021-04-21 | — | — | EP | claimed |
| US-10401747-B1 | Undercoat layer for imaging device | XEROX CORPORATION (US) | 2019-09-03 | — | — | US | claimed |
| EP-1339690-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | claimed |
| US-20040053965-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | claimed |
| CN-121609673-B | PDE4 inhibitor and preparation method and application thereof | WUYI UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| WO-2026051010-A1 | SCALE-UP PREPARATION METHOD FOR 6-BROMO-4-HYDROXYQUINOLINE | 上海再启生物技术有限公司 | 2026-03-12 | — | — | WO | disclosed |
| WO-2026051010-A1 | SCALE-UP PREPARATION METHOD FOR 6-BROMO-4-HYDROXYQUINOLINE | 上海再启生物技术有限公司 | 2026-03-12 | — | — | WO | disclosed |
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2025-07-03 | — | — | US | disclosed |
| CN-120035581-A | Amplifying preparation method of 6-bromo-4-hydroxyquinoline | 上海再启生物技术有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-120035581-A | Amplifying preparation method of 6-bromo-4-hydroxyquinoline | 上海再启生物技术有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20060009460-A1 | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | AGRIUS GROUP, LLC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005120509-A1 | QUINOLINE- AND ISOQUINOLINE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| EP-0518530-B1 | Improvements in or relating to excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5196421-A | Treatment of neurological disorders | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0518530-A2 | Improvements in or relating to excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1992-12-16 | — | — | EP | disclosed |
| US-5153196-A | Administering for reduction of neurotransmission in nervous system disorders | ELI LILLY AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | POT1, PARP15, TERT | SLC22A12 4275/4885NCF1 3197/4885ALK 4849/4885 |
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | SLC22A12 4578/4885NCF1 3570/4885ALK 914/4885 |
| US-20060009460-A1 | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | SLC22A12 2574/4885NCF1 2180/4885ALK 4689/4885 |
| US-20040053965-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1B, CACNA1E, CACNA1A | SLC22A12 3556/4885NCF1 334/4885ALK 4035/4885 |
| US-20210246128-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | TOP1, TOP2A, TOP2B | SLC22A12 2171/4885NCF1 1641/4885ALK 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.